Top of page Skip navigation

 Genesis Sessions 2019


08.00 Registration

09.00: Welcome from One Nucleus

09.15: Winners and Losers 2019

Mike Ward, Pharma Intelligence & Datamonitor

09.40: Keynote Presentation

Speaker tbc


10.05: Plenary Debate – New Horizons in the boardroom  

The question that will be debated is how the 21st century biotech C-suite and boardroom should look like? Gender, generation, background diversity is constantly praised but doesn’t seem to translate. Ideas on how to make it happen will be discussed.   

10.55: Closing Remarks


11.00: Coffee Break


11.30: Parallel Leadership Sessions 1


12.30: Lunch

Including a panel discussion and the announcement of the winner of the BioNewsRound Award


14.00: Parallel Leadership Sessions 2


15.00: Coffee Break


15.30: Parallel Leadership Sessions 3


16.35 – 17.35 Plenary Debate – What drives market investment in our industry? 

Panellists will discuss how our sector stands in the bigger economic picture and what factors influence market investments whether they are contextual like politics or specific like regulatory or technology evolution.  

17.35 – 17.40 Closing Remarks 

17.40 – 19.00 Drinks Reception


4 Parallel Leadership Sessions

Understanding Market Makers

If cash is king, understanding investment drivers is key. This stream will review three different therapeutic areas under the angle of their market and how it attracts investment. It will cover:

-          Anti-infection

-          Metabolic disorders

-          Immuno-oncology


Nurturing Digital Health Champions

This stream will highlight the key success factors in digital health with examples of success stories and enablers.

Redefining Therapeutics Areas

This stream will review areas of expertise and technologies that are contributing to redefining the scope of therapeutics areas.

-          Is prevention the new cure? With insights from healthcare and nutrition sciences and their contribution to therapeutics

-          New technology paradigms. Covering areas like bioelectronics, nanotechnologies or synthetic biology and their contribution to new therapeutics development

-          From rare disease to unique approach – with genomics being a game changer in rare diseases research, we’ll review how this can be translated to other areas       


Meeting Biotech Rising Stars

This stream will provide a snapshot of the future biotech landscape with presentations from leading investors portfolio companies